CN101085347B - 甲型肝炎-乙型肝炎-戊型肝炎联合疫苗 - Google Patents
甲型肝炎-乙型肝炎-戊型肝炎联合疫苗 Download PDFInfo
- Publication number
- CN101085347B CN101085347B CN200710024412A CN200710024412A CN101085347B CN 101085347 B CN101085347 B CN 101085347B CN 200710024412 A CN200710024412 A CN 200710024412A CN 200710024412 A CN200710024412 A CN 200710024412A CN 101085347 B CN101085347 B CN 101085347B
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- vaccine
- hev
- hav
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000010284 hepatitis E Diseases 0.000 title claims description 66
- 208000005252 hepatitis A Diseases 0.000 title claims description 31
- 208000002672 hepatitis B Diseases 0.000 title claims description 27
- 229940001442 combination vaccine Drugs 0.000 title claims description 14
- 229960005486 vaccine Drugs 0.000 claims abstract description 164
- 241000724675 Hepatitis E virus Species 0.000 claims abstract description 84
- 239000000427 antigen Substances 0.000 claims abstract description 64
- 102000036639 antigens Human genes 0.000 claims abstract description 64
- 108091007433 antigens Proteins 0.000 claims abstract description 64
- 241000709721 Hepatovirus A Species 0.000 claims abstract description 47
- 208000006454 hepatitis Diseases 0.000 claims abstract description 17
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 14
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 11
- 230000009849 deactivation Effects 0.000 claims description 86
- 241000700605 Viruses Species 0.000 claims description 58
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 21
- 239000000499 gel Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 239000000568 immunological adjuvant Substances 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 101710132601 Capsid protein Proteins 0.000 claims 1
- 101710169459 Secreted protein ORF2 Proteins 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 abstract description 12
- 238000011160 research Methods 0.000 abstract description 12
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 206010019799 Hepatitis viral Diseases 0.000 abstract description 6
- 201000001862 viral hepatitis Diseases 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 4
- 229960002520 hepatitis vaccine Drugs 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract 1
- 230000008521 reorganization Effects 0.000 description 94
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 62
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 56
- 229940124724 hepatitis-A vaccine Drugs 0.000 description 55
- 238000002347 injection Methods 0.000 description 42
- 239000007924 injection Substances 0.000 description 42
- 241000699666 Mus <mouse, genus> Species 0.000 description 39
- 210000002966 serum Anatomy 0.000 description 39
- 230000036039 immunity Effects 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 13
- 230000003053 immunization Effects 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000002649 immunization Methods 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 6
- 229940031551 inactivated vaccine Drugs 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 229920001503 Glucan Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- 208000009594 Animal Hepatitis Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 241000628923 Anadara sativa Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229940124872 Hepatitis B virus vaccine Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 1
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000010516 chain-walking reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000012297 crystallization seed Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229940031346 monovalent vaccine Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710024412A CN101085347B (zh) | 2007-06-15 | 2007-06-15 | 甲型肝炎-乙型肝炎-戊型肝炎联合疫苗 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710024412A CN101085347B (zh) | 2007-06-15 | 2007-06-15 | 甲型肝炎-乙型肝炎-戊型肝炎联合疫苗 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101085347A CN101085347A (zh) | 2007-12-12 |
CN101085347B true CN101085347B (zh) | 2010-05-19 |
Family
ID=38936630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200710024412A Active CN101085347B (zh) | 2007-06-15 | 2007-06-15 | 甲型肝炎-乙型肝炎-戊型肝炎联合疫苗 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101085347B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101564533B (zh) * | 2009-06-12 | 2012-01-04 | 东南大学 | 戊型肝炎蛋白-核酸复合疫苗及其制备方法 |
KR102157718B1 (ko) * | 2010-07-26 | 2020-09-18 | 큐 바이올로직스 인코포레이티드 | 면역원성 소염 조성물 |
CN102988975A (zh) * | 2012-11-30 | 2013-03-27 | 深圳康泰生物制品股份有限公司 | 甲型、乙型肝炎联合疫苗及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0339667A2 (en) * | 1988-04-28 | 1989-11-02 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Hepatitis A,B,-combined adjuvanted vaccine |
CN1596978A (zh) * | 2004-07-23 | 2005-03-23 | 中国医学科学院医学生物学研究所 | 甲型、乙型肝炎联合疫苗及其制备方法 |
CN1814286A (zh) * | 2005-11-29 | 2006-08-09 | 东南大学 | 乙型肝炎-戊型肝炎联合疫苗及其制备方法 |
US7144703B2 (en) * | 1998-05-01 | 2006-12-05 | Smithkline Beecham Biologicals, S.A. | Composition |
CN1883704A (zh) * | 2005-06-24 | 2006-12-27 | 东南大学 | 甲型肝炎-戊型肝炎联合疫苗及其制备方法 |
-
2007
- 2007-06-15 CN CN200710024412A patent/CN101085347B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0339667A2 (en) * | 1988-04-28 | 1989-11-02 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Hepatitis A,B,-combined adjuvanted vaccine |
US7144703B2 (en) * | 1998-05-01 | 2006-12-05 | Smithkline Beecham Biologicals, S.A. | Composition |
CN1596978A (zh) * | 2004-07-23 | 2005-03-23 | 中国医学科学院医学生物学研究所 | 甲型、乙型肝炎联合疫苗及其制备方法 |
CN1883704A (zh) * | 2005-06-24 | 2006-12-27 | 东南大学 | 甲型肝炎-戊型肝炎联合疫苗及其制备方法 |
CN1814286A (zh) * | 2005-11-29 | 2006-08-09 | 东南大学 | 乙型肝炎-戊型肝炎联合疫苗及其制备方法 |
Non-Patent Citations (2)
Title |
---|
董晨等.不同剂量配比的实验性甲型肝炎戊型肝炎联合疫苗的免疫原性研究.细胞与分子免疫学杂志第23卷 第2期.2007,第23卷(第2期),第130-133页. |
董晨等.不同剂量配比的实验性甲型肝炎戊型肝炎联合疫苗的免疫原性研究.细胞与分子免疫学杂志第23卷 第2期.2007,第23卷(第2期),第130-133页. * |
Also Published As
Publication number | Publication date |
---|---|
CN101085347A (zh) | 2007-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Enterovirus 71 vaccine: close but still far | |
RU2194531C2 (ru) | Поливалентные ассоциированные коклюшно-дифтерийно-столбнячно (акдс)-полиомиелитные вакцины | |
CN101402944B (zh) | 一种ev-71病毒毒种、人用灭活疫苗及其制备方法 | |
CN105749268A (zh) | 一种灭活的寨卡病毒疫苗 | |
BR112013017171B1 (pt) | composição combinada heptavalente estável | |
CN106999569A (zh) | 肠道病毒灭活的改进的方法、佐剂吸附及其获得的剂量减少的疫苗组合物 | |
CN101085347B (zh) | 甲型肝炎-乙型肝炎-戊型肝炎联合疫苗 | |
RU2447898C2 (ru) | Вакцина ipv-dpt | |
CN101991849A (zh) | 一种猪伪狂犬病灭活疫苗的制备方法 | |
CN102268411A (zh) | Ibdv无血清微载体悬浮培养增殖的方法 | |
CN103554254A (zh) | 一种抗人a组轮状病毒的鸡卵黄抗体及其制备方法和应用 | |
CN103333849A (zh) | 金黄色葡萄球菌突变株及其制备方法和应用 | |
CN104906569A (zh) | 一种百日咳疫苗制剂及其联合疫苗 | |
WO2024125100A1 (zh) | 一种ev71-ca16二价灭活疫苗及其制备方法和应用 | |
CN102010876A (zh) | 重组枯草芽孢杆菌ev71-vp1表达载体及其制备方法与应用 | |
CN100446813C (zh) | 甲型肝炎-戊型肝炎联合疫苗及其制备方法 | |
CN103614387B (zh) | 优化的猪圆环病毒2型Cap蛋白基因及其重组质粒和应用 | |
CN100482274C (zh) | 乙型肝炎-戊型肝炎联合疫苗及其制备方法 | |
CN104725503A (zh) | 一种红鳍东方鲀神经坏死病毒衣壳蛋白卵黄抗体及其应用 | |
CN103993032A (zh) | 一种制备重组脊髓灰质炎病毒样颗粒的方法 | |
CN102533629A (zh) | 禽脑脊髓炎病毒vp1蛋白亚单位疫苗的制备方法 | |
CN105541976A (zh) | 猪圆环病毒2型Cap基因修饰改造重组抗原及其应用 | |
CN108619502A (zh) | 一种基于重组载体蛋白的季节流感-rsv-流脑联合疫苗 | |
CN102174477B (zh) | 甲型肝炎病毒株sh及其二倍体细胞适应方法 | |
CN101863976B (zh) | 一种ev71病毒抗体的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201221 Address after: Floor 402, building 1, Kechuang accelerator, Kechuang Industrial Park, Chuzhou higher education Kechuang City, No. 1500, Hongwu East Road, Nanqiao District, Chuzhou City, Anhui Province, 239000 Patentee after: Chuzhou Fangzhou Pharmaceutical Co.,Ltd. Address before: 210096 No. four archway, 2, Jiangsu, Nanjing Patentee before: SOUTHEAST University |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Hepatitis A-B-E combined vaccine Effective date of registration: 20210510 Granted publication date: 20100519 Pledgee: Chuzhou Yinfeng financing Company limited by guarantee Pledgor: Chuzhou Fangzhou Pharmaceutical Co.,Ltd. Registration number: Y2021980003403 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220418 Granted publication date: 20100519 Pledgee: Chuzhou Yinfeng financing Company limited by guarantee Pledgor: Chuzhou Fangzhou Pharmaceutical Co.,Ltd. Registration number: Y2021980003403 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Hepatitis A-B-E combined vaccine Effective date of registration: 20220422 Granted publication date: 20100519 Pledgee: Chuzhou Yinfeng financing Company limited by guarantee Pledgor: Chuzhou Fangzhou Pharmaceutical Co.,Ltd. Registration number: Y2022980004613 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230414 Granted publication date: 20100519 Pledgee: Chuzhou Yinfeng financing Company limited by guarantee Pledgor: Chuzhou Fangzhou Pharmaceutical Co.,Ltd. Registration number: Y2022980004613 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Hepatitis A, hepatitis B, and hepatitis E combined vaccine Effective date of registration: 20230425 Granted publication date: 20100519 Pledgee: Chuzhou Yinfeng financing Company limited by guarantee Pledgor: Chuzhou Fangzhou Pharmaceutical Co.,Ltd. Registration number: Y2023980039148 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20100519 Pledgee: Chuzhou Yinfeng financing Company limited by guarantee Pledgor: Chuzhou Fangzhou Pharmaceutical Co.,Ltd. Registration number: Y2023980039148 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Hepatitis A Hepatitis B Hepatitis E Combination Vaccine Granted publication date: 20100519 Pledgee: Chuzhou Yinfeng financing Company limited by guarantee Pledgor: Chuzhou Fangzhou Pharmaceutical Co.,Ltd. Registration number: Y2024980012349 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |